Controlled Self‐Destructive Engineered Bacteria for Effective Immuno‐Photodynamic Therapy Against Melanoma
Advanced Healthcare Materials · 2025-07 · 14 (17)
DOI: 10.1002/adhm.202405210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 28.05.2025. Verfasst von Xinting Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Nanchang University, Nanchang, 330031, P. R. China. Hauptthemen laut MEDLINE: Photochemotherapy, Photosensitizing Agents, Melanoma, Experimental, Salmonella typhimurium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Jiangxi Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
The super aggressive and metastasizing nature of melanoma urgently calls for effective therapeutic scenarios. Recent advances in biohybrids comprising bacteria and chemical substances have demonstrated significant merits in treating cancer by attribute complementation. Here, through bioorthogonal chemistry, the developed photosensitizer (IN) is covalently anchored onto the surface of an attenuated Salmonella typhimurium strain (VNP) engineered with the programmed cell death protein 1 (PD‐1)‐encoding plasmid, creating controlled self‐destructive engineered bacteria (VNP‐mPD‐1@IN). After intravenous injection into B16F10 melanoma‐bearing mice, VNP‐mPD‐1@IN specifically accumulates within the tumor mediated by the hypoxic tropism of VNP, encoding PD‐1 within tumor cells and simultaneously triggering partial tumor cell apoptosis due to the self‐cytotoxicity of VNP. Once excited by long‐wavelength photons, IN on VNP‐mPD‐1@IN efficiently generates reactive oxygen species, which not only induces the apoptosis of tumor cells, but also triggers bacterial self‐destruction to eliminate potential biosafety concerns. The apoptosis of tumor cells leads to considerable immunogenic cell death to reprogram immune environment, which is powered by PD‐1‐mediated immune checkpoint blockage. As a result, effective immuno‐photodynamic therapy is realized to suppress the growth of primary and distant B16F10 tumors as well as prevent their metastasis. This study sheds light on the remolding of bacteria for effective cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Nanchang University, Nanchang, 330031, P. R. China.
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, 330047, P. R. China.
- Biomaterials Research Center, School of Biomedical Engineering, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, 510515, P. R. China.
- Department of Urology, Jiangxi Provincial Key Laboratory of Urinary System Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, P. R. China.
ORCID-Profile: Hao Wan
Förderung
- Jiangxi Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Xu, X., Zhang, Y., Tian, Y., Guo, L., Zhou, L., Wan, Y., Fang, Z., Ouyang, F., & Wan, H. (2025). Controlled Self‐Destructive Engineered Bacteria for Effective Immuno‐Photodynamic Therapy Against Melanoma. Advanced Healthcare Materials, 14(17). https://doi.org/10.1002/adhm.202405210
Vancouver
Xu X, Zhang Y, Tian Y, Guo L, Zhou L, Wan Y, et al. Controlled Self‐Destructive Engineered Bacteria for Effective Immuno‐Photodynamic Therapy Against Melanoma. Advanced Healthcare Materials. 2025;14(17). doi:10.1002/adhm.202405210
BibTeX
@article{Xu2025,
author = {Xu, Xinting and Zhang, Ying and Tian, Ye and Guo, Lan and Zhou, Lizhi and Wan, Yiqun and Fang, Ziqi and Ouyang, Fangyan and Wan, Hao},
title = {Controlled Self‐Destructive Engineered Bacteria for Effective Immuno‐Photodynamic Therapy Against Melanoma},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {17},
doi = {10.1002/adhm.202405210}
}
EUVIMED